Mesenchymal stem cells for immune modulation in systemic lupus erythematosus: From bench research to clinical applications

Authors

  • Andi R. Ginting Department of Internal Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia https://orcid.org/0000-0003-2464-9907
  • Delfitri Munir Department of Doctoral Program in Medical Sciences, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia; Department of Otorhinolaryngology-Head and Neck Surgery, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia; Pusat Unggulan Iptek Tissue Engineering, Universitas Sumatera Utara, Medan, Indonesia
  • Mustafa M. Amin Department of Doctoral Program in Medical Sciences, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia; Department of Psychiatry, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia https://orcid.org/0000-0003-0912-9372
  • Dewi M. Darlan Department of Doctoral Program in Medical Sciences, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia; Department of Parasitology, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia https://orcid.org/0000-0002-2434-3118
  • Agung Putra Stem Cell and Cancer Research Center, Semarang, Indonesia; Faculty of Postgraduate Biomedical Science, Universitas Islam Sultan Agung, Semarang, Indonesia
  • Muhammad Rusda Department of Doctoral Program in Medical Sciences, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia; Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
  • Erna Mutiara Faculty of Public Health, Universitas Sumatera Utara, Medan, Indonesia https://orcid.org/0000-0003-0766-9869
  • Evita Mayasari Department of Microbiology, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia https://orcid.org/0000-0002-9620-0941
  • Muhammad F. Rozi Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia

DOI:

https://doi.org/10.52225/narra.v4i3.994

Keywords:

Autoimmune, dysregulation, immunomodulation, immunosuppression, stem cell

Abstract

Systemic lupus erythematosus (SLE) is a prevalent autoimmune disease affecting multiple organ systems. Disease progression is inevitable as part of its natural course, necessitating aggressive therapeutic strategies, particularly with the use of immunosuppressants. Long-term use of steroids and other immunosuppressants is associated with significant adverse effects. Mesenchymal stem cells (MSCs) have been shown to modulate the immune response, leading to immunosuppressive effects against self-antigens. MSCs have demonstrated the ability to modulate several immune cell populations, contributing to favorable outcomes in controlling immune and inflammatory conditions. Recent evidence has shown an increase in Treg and Breg cell subsets following MSC administration, along with modulation of other immune cells, including dendritic cells, B cells, and T cells. However, the balance between MSC pro-inflammatory and anti-inflammatory phenotypic activation remains a critical factor in determining therapeutic outcomes. Various covariates also influence the efficacy of MSC therapy. The aim of this study was to provide a comprehensive overview of the utilization of mesenchymal stem cells (MSCs) in SLE treatment, leveraging their immunomodulatory and immunosuppressive capabilities. Understanding the fundamental preclinical effects of MSCs and recent findings from clinical studies may enhance the potential of MSC therapy in the management of SLE patients.

Downloads

Download data is not yet available.

Downloads

Issue

Section

Review Article

Citations